AstraZeneca (AZN) and Daiichi Sankyo’s ENHERTU has been approved in the US for the treatment of adult patients with unresectable or metastatic ...

The Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to brelovitug (BJT-778) for the treatment of chronic hepatitis delta (CHD).

Boehringer Ingelheim’s investigational schizophrenia candidate has failed to improve cognitive impairment or functioning in a ...

The US Food and Drug Administration (FDA) has granted approval for Zydus Lifesciences to proceed with a randomised Phase IIb ...

Pfizer Inc. (NYSE:PFE) revealed results from the Phase 3 BREAKWATER trial evaluating Braftovi (encorafenib) in combination ...

Please provide your email address to receive an email when new articles are posted on . The FDA has granted breakthrough therapy designation to Bluejay Therapeutics’ brelovitug for the treatment ...

for GC and a multi-regional Phase 1 trial (NCT05458219) for PDAC ongoing. IBI343 was granted breakthrough therapy designation (BTD) by China's National Medical Products Administration (NMPA ...

Penn Medicine is one of the first institutions to develop FDA-approved CAR T-cell therapies. By utilizing the power of the body’s own immune system, CAR T-cell therapy aims to help ... to moving into ...

Positive Phase 1b Data Confirms Overdose Protection for Highest Dosage Form of PF614-MPAR ~ SAN DIEGO, CA / ACCESS Newswire / January 22, 2025 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or ...

Innovent Biologics, Inc., announced that the Center for Drug Evaluation (CDE) of China's National Medical Products ...